David Hallal
CIK 1457477 · Chief Executive Officer · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$91.80M
Companies
5
Total Filings
115
Lifetime Open-Market Net
-$16.84M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | Director | — | $3.34 | — | $0 | 2 | 2026-06-04 |
| SRRK | Chief Executive Officer | 1,844,034 | $49.37 | $91.04M | -$3.97M | 15 | 2026-04-20 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | 0 | $10.15 | $0 | -$3.94M | 9 | 2025-08-29 |
| SEER | Director | 355,128 | $2.14 | $760.0K | $0 | 5 | 2024-06-14 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 99,210 | $9.81 | $973.3K | -$8.93M | 15 | 2024-06-07 |
Recent Filings · Page 3 of 12
115 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-12 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2022-10-21 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −600,000 | -$5.07M | EDGAR |
| 2022-09-30 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −400,000 | -$2.94M | EDGAR |
| 2022-08-01 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +3,253,796 | $15.00M | EDGAR |
| 2022-07-21 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −4,227 | -$22.5K | EDGAR |
| 2022-06-21 | SRRK | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | SEER | Grant (A) | +9,945 | $0 | EDGAR |
| 2022-06-10 | iTeos Therapeutics, Inc. (ITOS) Delisted | Mixed | — | -$487.2K | EDGAR |
| 2022-06-06 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −65,725 | -$241.1K | EDGAR |
| 2022-05-27 | SRRK | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.